Biological activities of guanidine compounds

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 10, 2009, Pages 1417-1448

  Saczewski, Franciszek ^a   Balewski, Łukasz ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Biological activity; Guanidine containing compounds; Guanidine containing peptides; Guanidine containing peptidomimetics; Guanidine containing peptoids; Guanidines; Medical applications

Indexed keywords

(5 (2 METHOXYPHENYL)FURAN 2 YL CARBONYL)GUANIDINE; 1 [2 (AMIDINOTHIO)ETHYL]GUANIDINE; 3 (1 ACETAMIDO 2 PROPYLPENTYL) 4 GUANIDINOCYCLOPENTANECARBOXYLIC ACID; 4,5 DIHYDRO 1H IMIDAZOL 2 YL [4 (4 ISOPROPOXYBENZYL)PHENYL]AMINE; AMILORIDE; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BETA SECRETASE INHIBITOR; BL 11282; CARIPORIDE; GUANIDINE DERIVATIVE; HISTAMINE AGONIST; ISOINDOLE DERIVATIVE; KAPPA OPIATE RECEPTOR ANTAGONIST; KR 3270; MELANOCORTIN RECEPTOR AGONIST; N (1 HYDROXY 2 NAPHTHOYL)ARGINYLPROLINAMIDE; NALTRINDOLE; NITRIC OXIDE SYNTHASE INHIBITOR; PEPTIDOMIMETIC AGENT; POLYPEPTIDE ANTIBIOTIC AGENT; QUINAZOLINONE DERIVATIVE; RO 3244019; RWJ 58643; SC 68448; SEROTONIN AGONIST; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANGINA PECTORIS; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ATTENTION DEFICIT DISORDER; BRAIN HEMORRHAGE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; DOWN SYNDROME; DRUG MECHANISM; DRUG RECEPTOR BINDING; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEPATITIS C; HUMAN; INFLUENZA; INSULIN TREATMENT; LEYDIG CELL TUMOR; NARCOLEPSY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PAIN; PATENT; REVIEW; SCHIZOPHRENIA; SEIZURE; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; DRUG CARRIERS; DRUG DESIGN; ENZYME INHIBITORS; FIBRINOLYTIC AGENTS; GENE TRANSFER TECHNIQUES; GUANIDINES; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR STRUCTURE; NITRIC OXIDE SYNTHASE; SODIUM-HYDROGEN ANTIPORTER; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70349763292     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770903216675     Document Type: Review

References (217)

1. Berlinck RGS, Burtoloso ACB, Kossuga MH. The chemistry and biology of organic guanidine derivatives. Nat Prod Rep 2008;25:919-954
2. Mori A, Cohen BD, Lowenthal A. Guanidines, historical, biochemical and clinical aspects of the naturally occurring guanidine compounds. Plenum, New York, 1985
3. Greenhill JV, Lue L. Amidines and guanidines in medicinal chemistry. In: Prog Med Chem 1993;30:203
4. Ishikawa T. Superbases for organic synthesis: guanidines, amidines, phosphazenes and related organocatalysts. J Wiley & Sons, 2009
5. Reetz MT, Bingel C, Harms K. Structure of carbanions having carbocations as counterions. J Chem Soc Chem Commun 1993;1558-1560
6. Krygowski TM, Cyranski MK, Anulewicz-Ostrowska R. Guanidine cation - an acyclic analogue of benzene? Pol J Chem 2001;75:1939-1942
7. Eckert-Maksic M, Glasovac Z, Troselj P, et al. Basicity of guanidines with heteroalkyl side chains in acetonitrile. Eur J Org Chem 2008: 5176-5184
8. Brzozowski Z, Saczewski F, Gdaniec M. Synthesis, molecular structure and anticancer activity of 1-allyl-3-amino-2-(4-chloro-2-mercaptobenzenesulfonyl) guanidine derivatives. Eur J Med Chem 2002;37:285-293 (Pubitemid 34310580)
9. Saczewski F. Functions containing an iminocarbonyl group and any elements other than a halogen and chalcogen. In: Katritzky AR, Taylor RJK, editors, Comprehensive organic functional group transformations II 6, Chapter 6.21, Elsevier Ltd; 2004. p. 605-660
10. Suhs T, Konig B. Synthesis of guanidines in solution. Mini-Rev Org Chem 2006;3:315-331
11. Katritzky AR, Rogovoy BV. Recent developments in guanylating agents. ARKIVOC 2005;49-87
12. Jensen KB, Braxmeier TM, Demarcus M, et al. Synthesis of guanidinium-derived receptor libraries and screening for selective peptide receptors in water. Eur J Chem 2002;8:1300-1309 (Pubitemid 34259552)
13. Simoni D, Invidiata FP, Manfredini S, et al. Facile synthesis of 2-nitroalkanes by tetramethylguanidine (TMG) catalyzed addition of primary nitroalkanes to aldehydes and alicyclic ketones. Tetrahedron Lett 1997;38:2749-2752 (Pubitemid 27154381)
14. Schug KA, Lindner W. Noncovalent binding between guanidinium and ionic groups: focus on biological and synthetic-based arginine/guanidinium interactions with phosph(on)ate and sulf(on)ate residues. Chem Rev 2005;105:67-114 (Pubitemid 40195930)
15. Gale PA. Preface and following articles of this special issue devoted to anion complexation. Coord Chem Rev 2006;250:2917
16. Wolfenden R, Andersson L, Cullis PM, et al. Affinities of amino acid side chains for solvent water. Biochemistry 1981;20:849-855
17. Springs B, Haake P. Equilibrium constants for association of guanidinium and ammonium ions with oxyanions. Bioorg Chem 1977;6:181-190
18. Meot-Ner M. The ionic hydrogen bond. Chem Rev 2005;195:213-284
19. Cole SL, Vassar R. BACE-1 structure and function in health and Alzheimer's disease. Curr Alzheimer Res 2008;5:100-120
20. Guo T, Hobbs DW. Development of BACE-1 inhibitors for Alzheimer's disease. Curr Med Chem 2006;13:1811-1829 (Pubitemid 43871758)
21. Shimizu H, Tosaki A, Kaneko K, et al. Crystal structure of an active form of BACE1, an enzyme responsible for amyloid β protein production. Mol Cell Biol 2008;28:3663-3671 (Pubitemid 351732903)
22. Garino C, Tomita T, Pietrancosta N, et al. Naphthyl and coumarinyl biarylpiperazine derivatives as highly potent human β-secretase inhibitors. Design, synthesis, and enzymatic BACE-1 and cell assays. J Med Chem 2006;49:4275-4285 (Pubitemid 44036671)
23. AstraZeneca AB. WO-120096; 2007
24. Gerritz S, Shi S, Zhu S, et al. US-0287287; 2006
25. Bristol-Myers Squibb Company. WO-002220; 2007
26. Bristol-Myers Squibb Company. WO-002214; 2007
27. Gerritz S, Good AC, Thompson III LA, et al. US-0015754; 2007
28. Yong-Jin WU, Gerritz S, Shi S, et al. US-0232581; 2007
29. Baihua HU. US-0183943; 2006
30. Baihua HU. US 088705; 2006
31. Cole DC, Manas ES, Stock JR, et al. Acylguanidines as small-molecule β-secretase inhibitors. J Med Chem 2006;49:6158-6161
32. Jennings LD, Cole DC, Stock JR, et al. Acylguanidine inhibitors of β-secretase: optimization of the pyrrole ring substituents extending into the S'1 substrate binding pocket. Bioorg Med Chem Lett 2008;18:767-771
33. Fobare WF, Solvibile WR, Robichaud AJ, et al. Thiophene substituted acylguanidines as BACE1 inhibitors. Bioorg Med Chem Lett 2007;17:5353-5356
34. Edwards PD, Albert JS, Sylvester M, et al. Application of fragment-based lead generation to the discovery of novel, cyclic amidine β-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. J Med Chem 2007;50:5912-5925
35. Goldin SM, Fischer JB, Knapp AG, et al. US-0265348; 2007
36. Yang H-YT, Fratta W, Majane EA, et al. Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptidesthat modulate the action of morphine. Proc Natl Acad Sci USA 1985;82:7757-7761 (Pubitemid 16204428)
37. Roumy M, Zajac J-M. Neuropeptide FF, pain and analgesia (Review). Eur J Pharmacol 1998;345:1-11
38. Panula P, Aarnisalo AA, Wasowicz K. Neuropeptide FF, a mammalian neuropeptide with multiple functions. Prog Neurobiol 1996;48:461-487
39. Caroff E, Steger M, Valdenaire O, et al. US-0194788; 2006
40. Actelion Pharmaceuticals Ltd. WO-023781; 2005
41. Actelion Pharmaceuticals Ltd. US-0123510; 2007
42. Taktix Corporation. WO-105779; 2003
43. Portoghese PS. Molecular recognition at kappa opioid receptors. Pure Appl Chem 2001;73:1387-1391
44. Clark RD, Jahangir A, Severance D, et al. Discovery and SAR development of 2-(phenylamino)imidazolines as prostacyclin receptor antagonists. Bioorg Med Chem Lett 2004;14:1053-1056 (Pubitemid 38167641)
45. Samad TA, Sapirstein A, Woolf CJ. Prostanoids and pain; unraveling mechanisms and revealing therapeutic targets. Trends Mol Med 2002;8:390-396 (Pubitemid 34826725)
46. Nakae K, Saito K, Iino T, et al. A prostacyclin receptor antagonist inhibits the sensitized release of substance P from rat sensory neurons. J Pharmacol Exp Ther 2005;315:1136-1142 (Pubitemid 41635400)
47. Bley KR, Bhattacharya A, Daniels DV, et al. RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacylin) receptor antagonists. Br J Pharmacol 2006;147:335-345 (Pubitemid 43214691)
48. Nichols DE, Nichols CD. Serotonin receptors. Chem Rev 2008;108:1614-1641
49. Abbott GMBH & CO KG. WO-022964; 2007
50. Abbott GMBH & CO KG. WO-082871; 2005
51. Hoffmann-La F. Roche AG. WO-000392; 2007
52. Peters J-U, Lübbers T, Alanine A, et al. Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: optimising brain penetration. Bioorg Med Chem Lett 2008;18:262-266
53. Lopez-Tudanca PL, Labeaga L, Innerarity A, et al. Synthesis and pharmacological characterization of a new benzoxazole derivative as potent 5-HT3 receptor agonist. Bioorg Med Chem 2003;11:2709-2714 (Pubitemid 36682994)
54. Glennon RA, Daoud MK, Dukat M, et al. Arylguanidine and arylbiguanide binding at 5-HT3 serotonin receptors: a QSAR study. Bioorg Med Chem 2003;11:4449-4454 (Pubitemid 37103115)
55. Cone RD. Melanocortins receptors. Humana Press Inc. New Jersey 2000
56. Xiao LL, Xu B, Luo J, et al. US-0004743; 2007
57. Chiron Corporation, Glaxo-Smithkline. US-0059662; 2005
58. Melacure Therapeutics AB. WO-013509; 2003
59. Holder JR, Bauzo RM, Xiang Z, et al. Design and pharmacology of peptoids and peptide-peptoid hybrids based on the melanocortin agonists core tetrapeptide sequence. Bioorg Med Chem Lett 2003;13:4505-4509 (Pubitemid 37490846)
60. Fotsch C, Smith DM, Adams JA, et al. Design of a new peptidomimetic agonist for the melanocortin receptors based on the solution structure of the peptide ligand, Ac-Nle-cyclo[Asp-Pro-DPhe-Arg-Trp-Lys]-NH2. Bioorg Med Chem Lett 2003;13:2337-2340
61. Mazur AW, Kulesza A, Mishra RK, et al. Novel tetrahydropyran-based peptidomimetics from a bioisosteric transformation of a tripeptide. evidence of their activity at melanocortin receptors. Bioorg Med Chem 2003;11:3053-3063 (Pubitemid 36773564)
62. Adrian Wai-Hing Cheung, Danho W, Swistok J, et al. Structure-activity relationship of linear peptide Bu-His-DPhe-Arg-Trp-Gly-NH2 at the human melanocortin-1 and -4 receptors: arginine substitution. Bioorg Med Chem Lett 2002;12:2407-2410 (Pubitemid 34879877)
63. Al-Obedi F, Hadley ME, Pettitt BM, et al. Design of new class of superpotent cyclic α-melanotropins based on quenched dynamic simulations. J Am Chem Soc 1989;111:3413-3416
64. Wessells H, Gralnek D, Dorr R, et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urologia 2000;56:641-646 (Pubitemid 30706241)
65. Stark H. Histamine receptors: review No1. Biotrend Rev 2007;1-9
66. Sheng-Xue xie, Ghorai P, Qi-Zhuang YE, et al. Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated imidazolylpropylguanidines. J Pharmacol Exp Ther 2006;317:139-146
67. Ghorai P, Kraus A, Keller M, et al. Acylguanidines as bioisisteres of guanidines: NG-acylated imidazolylpropylguanidines, a new class of histamine H2 receptor agonists. J Med Chem 2008;51:7193-7204
68. Igel P, Schneider E, Schnell D, et al. NG-Acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the NG-substituent. J Med Chem 2009 :Article ASAP
69. Bertinaria M. H3 receptor ligands: new imidazole H3-antagonists endowed with NO-donor properties. Il Pharmaco 2003;58:279-283
70. Linney ID, Buck IM, Harper EA, et al. Design, synthesis, and structure-activity relationships of novel non-imidazole histamine H3 receptor antagonists. J Med Chem 2000;43:2362-2370 (Pubitemid 30431934)
71. Lim HD, Smits RA, Bakker RA, et al. Discovery of S-(2-guanidynylethyl)- isothiourea (VUF 8430) as a potent nonimidazole histamine H4 receptor agonist. J Med Chem 2006;43:6650-6651
72. Constanzo MJ, Yabut SC, Almond HR, et al. Potent, small-molecule inhibitors of human mast cell tryptase. antiasthmatic action of a dipeptide-based trasition-state analogue containing a benzothiazole ketone. J Med Chem 2003;46:3865-3876
73. Fresno MD, Fernandez-Forner D, Miralpeix M, et al. Combinatorial approaches towards the discovery of new tryptase inhibitors. Bioorg Med Chem Lett 2005;15:1659-1664 (Pubitemid 40312548)
74. Kanatani A, Ishihara A, Asahi S, et al. Potent Neuropeptide YY1 receptor antagonist, 1229U91: blockade of neuropeptide Y-induced and physiological food intake. Endocrinology 1996;137:3177-3182 (Pubitemid 26250160)
75. Aquino CJ, Ramanjulu JM, Heyer D, et al. Synthesis and structure activity relationship of guanidines as NPY Y5 antagonists. Bioorg Med Chem 2004;12:2691-2708 (Pubitemid 38542794)
76. Keana JFW, Weber E. US-5574070
77. AstraZeneca AB. US-7001904; 2006
78. Voet T, Talareva K, Owsianik G, et al. Sensing with TRP channels. Nat Chem Biol 2006;1:85-92
79. Appendino G, Munoz E, Fiebich BL. TRPV1 (vanilloid receptor, capsaicin receptor) agonists and antagonists. Exp Opin Ther Patents 2003;13:1825-1837
80. Quintanar-Audelo M, Fernandez-Carvajal A, Nest WVD, et al. Design and synthesis of indole-based peptoids as potent noncompetitive antagonists of transient receptor potential vanilloid 1. J Med Chem 2007;50:6133-6143
81. Masereel B, Pochet L, Laeckmann D. An overview of inhibitors of Na+/H+ exchanger. Eur J Med Chem 2003;38:547-554
82. Rui Zhang, Lei L, Yun-Gen Xu, et al. Benzimidazol-2-yl or benzimidazol-2-ylthiomethylbenzoylguanidines as novel Na+/H+ exchanger inhibitors, synthesis and protection against ischemic-reperfusion injury. Bioorg Med Chem Lett 2007;17:2430-2433 (Pubitemid 46507795)
83. Juno Kim, Yi-Sook Jung, Vonsun Han, et al. Pharmacodynamic characteristics and cardioprotective effects of new NHE1 inhibitors. Eur J Pharmacol 2007;567:131-138
84. Aventis Pharma Deutschland GMBH. WO-101450; 2003
85. Nicholas Piramal India Limited. WO-051476; 2006
86. Sunkyung Lee, Kyu Yang YI, Sun Kyung Hwang, et al. (5-Arylfuran-2- ylcarbonyl) guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1. J Med Chem 2005;48:2882-2891
87. Kwang-Seok OH, Ho Won Seo, Kyu Yang YI, et al. Effects of KR-33028, a novel Na+/H+ exchanger-1 inhibitor, on ischemia and reperfusion-induced myocardial infarction in rats and dogs. Fundam Clin Pharmacol 2007;21:255-263
88. Mi Jeong Kim, Chang-Hyun Moon, Mi-Young Kim, et al. KR-32570, a novel Na+/H+ exchanger-1 inhibitor, attenuates hypoxia-induced cell death through inhibition of intracellular Ca2+ overload and mitochondrial death pathway in H9c2 cells. Eur J Pharmacol 2005;525:1-7
89. Bao Xin-Hua, Lu Wen-Cong, Liu Liang, Chen Nian-Yi. Hyper-polyhedron model applied to molecular screening of guanidines as Na/H exchange inhibitors. Acta Pharmacol Sin 2003;24:472-476
90. Wen-Ting Xu, Ning Jin, Jing Xu, et al. Design, synthesis and biological evaluation of novel substituted benzoylguanidine derivatives as potent Na+/H+ exchanger inhibitors. Bioorg Med Chem Lett 2009;19:3283-3287
91. Rui Zhang, Lin Lei, Yun-Gen XU, et al. Benzimidazol-2-ylthiomethyl benzoylguanidines as novel Na+/H+ exchanger inhibitors, synthesis and protection against ischemic-reperfusion injury. Bioorg Med Chem Lett 2007;17:2430-2433
92. Hobbs AJ, Higgs A, Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annu Rev Pharmacol Toxicol 1999;39:191-220 (Pubitemid 29222557)
93. Kerwin JF, Lancaster JR, Feldman PL. Nitric oxide: a new paradigm for second messengers. J Med Chem 1995;38:4343-4362
94. Martin NI, Beeson WT, Woodward JJ, Marletta MA. NG-Aminoguanidines from primary amines and the preparation of nitric oxide synthase inhibitors. J Med Chem 2008;51:924-931 (Pubitemid 351304699)
95. Cesnek M, Holý A, Masojídková M, Zídek Z. Synthesis of 9-alkyl nad 9-heteroalkyl substituted 2-amino-6-guanidinopurines and their influence on the NO-production in macrophages. Bioorg Med Chem 2005;13:2917-2926 (Pubitemid 40387500)
96. Bertinaria M, Stilo AD, Tosco P, et al. 3-(1H-Imidazol-4-yl) propylguanidines containing furoxan moieties: a new class of H3-antagonists endowed with NO-donor properties. Bioorg Med Chem 2003;11:1197-1205 (Pubitemid 36293516)
97. Fishlock D, Perdicakis B, Montgomery HJ, et al. Synthesis and evaluation of trans 3,4-cyclopropyl L-arginine analogues as isoform selective inhibitors of nitric oxide synthase. Bioorg Med Chem 2003;11:869-873 (Pubitemid 36287046)
98. Rossiter S, Smith CL, Malaki M, et al. Selective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolase. J Med Chem 2005;48:4670-4678 (Pubitemid 40993426)
99. UCL Biomedica PLC. WO-051314; 2006
100. UCL Business PLC. AU-303610; 2006
101. Vlasuk GP. In new therapeutic agents in thrombosis and thrombolysis. In: Sasahara AA, Loscalzo J, editors, Marcel Dekker; Chapter 15. New York, 1997
102. Coburn CA. Small-molecule direct thrombin inhibitors: 1997-2000. Exp Opin Ther Pat 2001;11:721-738
103. Simone GD, Menchise V, Omaggio S, et al. Design of weakly basic thrombin inhibitors incorporating novel P1 binding functions: molecular and X-ray crystallographic studies. Biochemistry 2003;42:9013-9021 (Pubitemid 36935409)
104. Aventis Pharma Deutschland GMBH. US-0143419; 2005
105. Novo Nordisk Healthcare A/G. US-0205648; 2006
106. Wei BI, Cai J, Liu S, et al. Design, synthesis and cardioprotective effect of a new class of dual-acting: Phenolic tetrahydro-β-carboline RDG peptidomimetic conjugates. Bioorg Med Chem 2007;15:6909-6919 (Pubitemid 47451801)
107. Polla MO, Tottie L, Norden C, et al. Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa). Bioorg Med Chem 2004;12:1151-1175 (Pubitemid 38251306)
108. Bosemberg LH, Zyl DGV. The mechanism of action of oral antidiabetic drugs: a review of recent literature. JEMDSA 2008;13: 80-86
109. AstraZeneca AB. US-0149614; 2007
110. Merck Patent GMBH. WO-076963; 2002
111. Venkateswarlu Y. US-0222168; 2005
112. Merrer YL, Gauzy L, Gravier-Pelletier C, et al. Synthesis of C2-symmetric guanidino-sugars as potent inhibitors of glycosidases. Bioorg Med Chem 2000;8:307-320 (Pubitemid 30122771)
113. Parmee ER. US-0105930; 2007
114. Nitto Denko Corporation. WO-044063; 2006
115. Karageozian VH. US-0105950; 2007
116. Tassoni E, Giannessi F, Brunetti T, et al. Novel substituted aminoalkylguanidines as potential antihyperglycemic and food intake-reducing agents. J Med Chem 2008;51:3073-3076 (Pubitemid 351821867)
117. Bahekar RH, Jain MR, Goel A, et al. Design, synthesis, and biological evaluation of substituted-N-(thieno[2,3-b]pyridin-3-yl)-guanidines, N-(1H-pyrrolo[2,3-b] pyridin-3-yl)-guanidines, and N-(1H-indol-3-yl)-guanidines. Bioorg Med Chem 2007;15:3248-3265 (Pubitemid 46505269)
118. Mousa SA, Cheresh DA. Recent advances in cell adhesion molecules and extracellular matrix proteins: potential clinical implications. Drug Discov Today 1997;2:187-199
119. Wiesner S, Legate KR, Fässler R. Review. Integrin-acting interactions. Cell Mol Life Sci 2005;62:1081-1099
120. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-687
121. Massia SP, Ehteshami G. US-0246104; 2006
122. Carron CP, Meyer DM, Pegg JA, et al. A peptidomimetic antagonist of the integrin αv β 3 inhibits leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res 1998;58:1930-1935
123. Penning TD, Russell MA, Chen BB, et al. Synthesis of cinnamic acids and related isosteres as potent and selective αvβ3 receptor antagonists. Bioorg Med Chem Lett 2004;14:1471-1476 (Pubitemid 38299431)
124. Dechantsreiter MA, Planker E, Matha B, et al. N-Methylated cyclic RGD peptides as highly active and selective αVβ3 integrin antagonists. J Med Chem 1999;42:3033-3040 (Pubitemid 29384038)
125. McCusker CF, Kocienski PJ, Boyle T, et al. Solid-phase synthesis of c(RGDfK) derivatives: on-resin cyclisation and lysine functionalisation. Bioorg Med Chem Lett 2002;12:547-549
126. Banfi L, Basso A, Damonte G, et al. Synthesis and biological evaluation of new conformationally biased integrin ligands based on tetrahydroazoninone scaffold. Bioorg Med Chem Lett 2007;17:1341-1345 (Pubitemid 46240835)
127. Peyman A, Wehner V, Knolle J, et al. RDG mimetics containing a central hydantoin scaffold: αVβ3 vs αIIbβ3 selectivity requirements. Bioorg Med Chem Lett 2000;10:179-182
128. Bubenik M, Meerovitch K, Bergeron F, et al. Thiophene-based vitronectin receptor antagonists. Bioorg Med Chem Lett 2003;13:503-506
129. Burdick DJ, Stanley MS, Oare D, et al. US-6667318; 2003
130. The Ohio State University Research Foundation. WO-044130; 2005
131. Kulp SK, Ya-Ting Yang, Chin-Chun Hung, et al. 3-Phosphoinositide- dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2- independent target for celecoxib in prostate cancer cells. Cancer Res 2004;15:1444-1451
132. Rockway TW. Selective urokinase inhibitors based on substituted aryl guanidines. Exp Opin Ther Pat 2001;11:1975-1977
133. Rosenberg S. Modulators of the urokinase-type plasminogen activation system for cancer. Exp Opin Ther Pat 2000;10:1843-1852
134. Wilex AG. US-7.049.460 B1; 2006
135. Fish PV, Barber CG, Brown DG, et al. Selective urokinase-type plasminogen activator inhibitors 4 1-(7-Sulfonamidoisoquinolinyl) guanidines. J Med Chem 2007;50:2341-2351
136. Joossens J, Ali OM, El-Sayed I, et al. Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties. J Med Chem 2007;50:6638-6646
137. Ohara K, Smietana M, Restouin A, et al. Amine-guanidine switch: a promising approach to improve DNA binding and antiproliferative activities. J Med Chem 2007;50:6465-6475 (Pubitemid 350309086)
138. Park M, Toporowski JW, Bruice TC. Ribonucleic guanidine demonstrates an unexpected marked preference for complementary DNA rather than RNA. Bioorg Med Chem 2006;14:1743-1749 (Pubitemid 43199508)
139. Dempcy RO, Browne KA, Bruice TC. Synthesis of a thymidyl pentamer of deoxiribonucleic guanidine and binding studies with DNA homopolynucleotides. Proc Natl Acad Sci USA 1995;92:6097-6101
140. Linkletter BA, Szabo IE, Bruice TC. Solid-phase synthesis of oligopurine deoxynucleic guanidine (DNG) and analysis of binding with DNA oligomers. Nucleic Acids Res 2001;29:2370-2376
141. Szabo IE, Bruice TC. DNG cytidine: synthesis and binding properties of octameric guanidinium-linked deoxycytidine oligomer. Bioorg Med Chem 2004;12:4233-4244
142. Xiaohua Zhang, Bruice TC. Complexation of single strand telomere and telomerase RNA template polyanions by deoxyribonucleic guanidine (DNG) polycations: plausible anticancer agents. Bioorg Med Chem Lett 2008;18:665-669
143. Toporowski JW, Reddy SY, Bruice TC. Comparison of positively charged DNG with DNA duplexes: a computational approach. Bioorg Med Chem 2005;13:3691-3698
144. Challa H, Bruice T. Deoxynucleic guanidine: synthesis and incorporation of purine nucleosides into positively charged DNG oligonucleotides. Bioorg Med Chem 2004;12:1475-1481 (Pubitemid 38296538)
145. Alarcon K, Demeunynck M, Lhomme J, et al. Potentiation of BCNU cytotoxicity by molecules targeting abasic lesions in DNA. Bioorg Med Chem 2001;9:1901-1910 (Pubitemid 32651926)
146. Geopharma Produktions GMBH. EP-1734064; 2004
147. Zhidong MA, Saluta G, Kucera GL, Bierbach U. Effect of linkage geometry on biological activity in thiourea- and guanidine-substituted acridines and platinium acridines. Bioorg Med Chem Lett 2008;18:3799-3801 (Pubitemid 351802253)
148. Lafrate AL, Gunther JR, Carlson KE, Katzenellenbogen JA. Synthesis and biological evaluation of guanylhydrazone coactivator binding inhibitors for the estrogen receptor. Bioorg Med Chem 2008;16:10075-10084
149. Shao D, Berrodin TJ, Manas E, et al. Identification of novel estrogen receptor α antagonists. J Steroid Biochem Mol Biol 2004;88:351-360 (Pubitemid 38625599)
150. Jieying Zhong, Ying Chau. Antitumor activity of a membrane lytic peptide cyclized with a linker sensitive to membrane type 1-matrix metalloproteinase. Mol Cancer Ther 2008;7:2933-2940
151. Mader JS, Hoskin DW. Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs 2006;15:933-946 (Pubitemid 44177845)
152. Brown JR, Nishimura Y, Esko JD. Synthesis and biological evaluation of gem-diamine 1-N-iminosugars related to L-iduronic acid as inhibitors of heparan sulfate 2-O-sulfotransferase. Bioorg Med Chem Lett 2006;16:532-536 (Pubitemid 43014832)
153. Raffel DM, Jung Y-W, Gildersleeve DL, et al. Radiolabeled phenethylguanidines: novel imaging agents for cardiac sympathetic neurons and adrenergic tumors. J Med Chem 2007;50:2078-2088
154. Chen XI, Liu C, Thurkauf A, Louise-May S. US-0100225; 2006
155. Achillion Pharmaceuticals, Inc. WO-095345; 2005
156. The Regents of the University of California. WO-016343; 2005
157. Olszewski A, Sato K, Aron ZD, et al. Guanidine alkaloid analogs as inhibitors of HIV-1 Nef interactions with p53, actin, and p56lck. Proc Natl Acad Sci USA 2004;101:14079-14084 (Pubitemid 39305033)
158. Itzstein MV, Wen-Yang WU, KOK GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993;363:418-423 (Pubitemid 23179386)
159. Xiang YI, Zongru GUO, Chu FM. Study on molecular mechanism and 3D-QSAR of influenza neuraminidase inhibitors. Bioorg Med Chem 2003;11:1465-1474
160. Goodman M, Tar Y, Baker T, et al. US-6525182; 2003
161. Chand P, Bantia S, Kotian PL, et al. Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo. Bioorg Med Chem 2005;13:4071-4077 (Pubitemid 40725039)
162. Babu YS. WO-095218; 2007
163. Masuda T, Shibuya S, Arai M, et al. Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir. Bioorg Med Chem Lett 2003;13:669-673 (Pubitemid 36298465)
164. Warda M, Lindhardt RJ, Marks RM. Patents related to dengue virus infection. Exp Opin Ther Patents 2002;12:1127-1143 (Pubitemid 34919196)
165. Woodmansee AN, Shi P-Y. Recent developments in West Nile virus vaccine and antiviral therapy. Exp Opin Ther Patents 2003;13:1113-1125 (Pubitemid 36986935)
166. Ganesh VK, Muller N, Judge K, et al. Identification and characterisation of nonsubstrate based inhibitors of the essential dengue and West Nile virus proteases. Bioorg Med Chem 2005;13:257-264 (Pubitemid 39575709)
167. Li J, Lim SP, Beer D, et al. Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J Biol Chem 2005;280:28766-28774 (Pubitemid 41105778)
168. Zheng Yin, Patel SJ, Wei-Ling Wang, et al. Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorg Med Chem Lett 2006;16:40-43
169. Wei RG, Arnaiz DO, Chou Y-L, et al. CCR5 receptor antagonists: discovery and SAR study of guanylhydrazone derivatives. Bioorg Med Chem Lett 2007;17:231-234 (Pubitemid 44959956)
170. Hensler ME, Bernstein G, Nizet V, Nefzi A. Pyrrolidine bis-cyclic guanidines with antimicrobial activity against drug-resistant Gram-positive pathogens identified from a mixture-based combinatorial library. Bioorg Med Chem Lett 2006;16:5073-5079 (Pubitemid 44247706)
171. Chang-Hyun OH, Jung-Hyuck CHO. Synthesis and biological evaluation of 1β-methylcarbapenems having guanidino moieties. Eur J Med Chem 2006;41:50-55 (Pubitemid 43276058)
172. Yoshizawa H, Kubota T, Itani H, et al. New broad-spectrum parenteral cephalosporins exhibiting potent activity against both methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Part 3: 7β-[2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-ethoxyiminoacetamido] cephalosporins bearing 4-[3-(aminoalkyl)-ureido]-1-pyridinium at C-3′. Bioorg Med Chem 2004;12:4221-4231
173. Glukhov E, Stark M, Burrows LL, Deber CM. Basis for selectivity of cationic antimicrobial peptides for bacterial versus mammalian membranes. J Biol Chem 2005;280:33960-33967 (Pubitemid 41443116)
174. De Yang, Biragyn A, Hoover DM, et al. Multiple roles of antimicrobial defensis, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol 2004;22:181-245
175. Tomasinsig L, Zanetti M. The cathelicidins - structure, function and evolution. Curr Protein Pept Sci 2005;6:23-34
176. Haug BE, Strom MB, Svendsen JS. The medicinal chemistry of short lactoferricin-based antibacterial peptides. Curr Med Chem 2007;14:1-8
177. Haug BE, Stensen W, Kalaaji M, et al. Synthetic antimicrobial peptidomimetics with therapeutic potential. J Med Chem 2008;51:4306-4314 (Pubitemid 352032455)
178. Lindgren M, Hallbrink M, Prochiantz A, Langel Ü. Cell-penetrating peptides. Trends Pharmacol Sci 2000;21:99-103
179. Nekhotiaeva N, Elmquist A, Rajarao GK, et al. Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides. FASEB J 2004;18:394-396
180. Schröder T, Schmitz K, Schepers UTE, et al. Solid-phase synthesis, bioconjugation, and toxicology of novel cationic oligopeptoids for cellular drug delivery. Bioconjug Chem 2007;18:342-354 (Pubitemid 46493504)
181. Schröder T, Niemeier N, Afonin S, et al. Peptoidic amino- and guanidinium-carrier systems: targeted drug delivery into the cell cytosol or the nucleus. J Med Chem 2008;51:376-379 (Pubitemid 351252262)
182. Qian L, Guan Y, Xiao H, et al. Modified guanidine polymers: synthesis and antimicrobial mechanism revealed by AFM. Polymer 2008;49:2471-2475
183. Kratzer C, Tobudic S, MacFelda K, et al. In vivo activity of a novel polymeric guanidine in experimental skin infection with methicilin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007;51:3437-3439
184. Wu W, Sil D, Szostak ML, et al. Structure-activity relationships of lipopolysaccharide sequestration in guanylhydrazone-bearing lipopolyamides. Bioorg Med Chem 2009;17:709-715
185. Sokolov VV, Kozhushkov SI, Nikolskaya S, et al. Total synthesis of TAN-1057 A/B, a new dipeptide antibiotic from Flexibacter sp. PK-74. Eur J Org Chem 1998;777-783 (Pubitemid 128534925)
186. Brands M, Endermann R, Gahlmann R, et al. Dihydropyrimidinones-A new class of anti-staphylococcal antibiotics. Bioorg Med Chem Lett 2003;13:241-245 (Pubitemid 35441343)
187. Whitaker BI, Busnel R-G. US-0053516; 2005
188. General Electric Company (US). CA-2528009; 2005
189. Pavlovna AZ, Mitrofanovna BE, Nikolaevich VG, et al. RU-2275193; 2006
190. Bode Chemie GMBH & CO. EP-1661586; 2005
191. Lowe CR, Lawden KH. US-0014678; 2005
192. Bromberg L, Hatton TA. Poly(N-vinylguanidine): characterization, and catalytic and bactericidal properties. Polymer 2007;48:7490-7498 (Pubitemid 350192511)
193. David L. WO-135380; 2007
194. Hui-Hang Hua, Peng J, Fronczek MTFR, et al. Crystallographic and NMR studies of antiinfective tricyclic guanidine alkaloids from the sponge Monanchora unguifera. Bioorg Med Chem 2004;12:6461-6464 (Pubitemid 39535169)
195. Rodrìguez F, Rozas I, Kaiser M, et al. New bis(2-aminoimidazoline) and bisguanidine DNA minor groove binders with potent in vivo antitrypanosomal and antiplasmodial activity. J Med Chem 2008;51:909-923 (Pubitemid 351304698)
196. Bakunova SM, Bakunov SA, Patrick DA, et al. Structure-activity study of pentamidine analogues as antiprotozoal agents. J Med Chem 2009;52:2016-2035
197. Dardonville C, Barrett MP, Brun R, et al. DNA binding affinity of bisguanidine and bis(2-aminoimidazoline) derivatives with in vivo antitrypanosomal activity. J Med Chem 2006;49:3748-3752 (Pubitemid 43902480)
198. Guetzoyan L, Ramiandrasoa F, Dorizon H, et al. In vitro efficiency of new acridyl derivatives against Plasmodium falciparum. Bioorg Med Chem 2007;15:3278-3289
199. Guan J, Zhang Q, Montip G, et al. Structure identification and prophylactic antimalarial efficacy of 2-guanidinoimidazolidinedione derivatives. Bioorg Med Chem 2005;13:699-704 (Pubitemid 40093612)
200. Jian Guan, Xihong Wang, Smith K, et al. Malaria causal prophylactic activity of imidazolidinedione derivatives. J Med Chem 2007;50:6226-6231
201. Solomon VR, Puri SK, Srivastava K, Katti SB. Design and synthesis of new antimalarial agents from 4-aminoquinoline. Bioorg Med Chem 2005;13:2157-2165 (Pubitemid 40261135)
202. Bossche HV. Echinocandins - an update. Exp Opin Ther Patents 2002;12:151-167
203. Weibo Wang, Qun Li, Hasvold L, et al. Discovery, SAR, synthesis, pharmacokinetic and biochemical characterization of A-192411: a novel fungicidal lipopeptide-(I). Bioorg Med Chem Lett 2003;13:489-493
204. Sakuda S, Isogaim A, Suzuki A, Yamada Y. Chemistry and biochemistry of the chitinase inhibitors, allosamidins. Actinomycetol 1993;7:50-57
205. Omura S, Arai N, Yamaguchi Y, et al. Argifin, a new chitinase inhibitor, produced by Gliocladium sp. FTD-0668 - I. Taxonomy, fermentation, and biological activities. J Antibiot 2000;53:603-608 (Pubitemid 30440450)
206. Gouda H, Sunazuka T, Iguchi K, et al. Computer-aided rational molecular design of argifin-derivatives with increased inhibitory activity against chitinase B from Serratia marcescens. Bioorg Med Chem Lett 2009;19:2630-2633
207. Braunerovà G, Buchta V, Palàt K Jr, et al. Synthesis and in vitro antifungal activity of 4-substituted phenylguanidinium salts. Il Farmaco 2004;59:443-450
208. Maiti KK, Lee WS, Takeuchi T, et al. Guanidine-containing molecular transporters: Sorbitol-based transporters show high intracellular selectivity toward mitochondria. Angew Chem 2007;119:5984-5988
209. Wender AP, Christopher L, Deusen V, et al. US-7067698; 2006
210. Rothbard BJ, Wender AP, et al. US-7169814; 2007
211. Tor Y, Luedtke N. US-0185040; 2007
212. Maiti KK, Ock-Youm Jeon, Woo Sirl Lee, Sung-Kee Chung. Design, synthesis, and delivery properties of novel guanidine-containing molecular transporters built on dimeric inositol scaffolds. Chem Eur J 2007;13:762-775
213. Mizuki Kitamatsu, Takanori Kubo, Rino Matsuzaki, et al. Carrier PNA for sarna delivery into cells. Bioorg Med Chem Lett 2009;19:3410-3413
214. Zuhorn IS, Engberts JBFN, Hoekstra D. Gene delivery by cationic lipid vectors: overcoming cellular. Eur Biophys J 2007;36:349-362 (Pubitemid 46626209)
215. Martin B, Sainlos M, Aissaoui A, et al. The design of cationic lipids for gene delivery. Curr Pharm Des 2005;11:375-394 (Pubitemid 40277864)
216. Uddin SN. Cationic lipids used in non-viral gene delivery systems. Biotechnol Mol Biol Rev 2007;2:58-67
217. Ilies M, Seitz WA, Balaban AT. Cationic lipids in gene delivery: Principles, vector design and therapeutical applications. Curr Pharm Des 2002;8:2441-2473 (Pubitemid 35339324)